Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

Background: Effective treatment for metastatic colorectal cancer (mCRC) remains an unmet need. CD47 overexpression on mCRC cells is associated with a poor prognosis. The ELEVATE CRC study evaluated magrolimab (CD47 inhibitor) plus bevacizumab-5-fluorouracil, irinotecan and leucovorin (FOLFIRI) in mC...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	M. Fakih, S. Gill, K. Sampat, D.L. Chan, G. Fisher, M. Cruz-Correa, H.-J. Lenz, P. Garcia-Alfonso, F. Forget, S. Lonardi, J. Krauss, E. Chen, A. Cubillo Gracian, Y. Liu, N. van Buuren, J. Shao, M. Dong, A. Chen, M. Tejani, J.R. Hecht
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-06-01
Saila:	ESMO Gastrointestinal Oncology
Gaiak:	metastatic colorectal cancer magrolimab bevacizumab FOLFIRI
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2949819826000245
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!